The Atherogenic Index Log (Triglyceride/HDL‑Cholesterol) as a Biomarker to Identify Type 2 Diabetes Patients with Poor Glycemic Control

Mani Nosrati, Mina Safari, Ahad Alizadeh, Mehran Ahmadi, Abdolkarim Mahrooz


Background: Identifying appropriate biomarkers for predicting type 2 diabetes (T2D) patients with increased HbA1c may prove helpful in preventing increased risk of cardiovascular disease (CVD). The present study was conducted to analyze the diagnostic performance of the atherogenic index log (TG/HDL‑C) in T2D patients with increased HbA1c. Methods: Patients with T2D were classified into two groups according to having an HbA1c <8% or ≥8%. Atherogenic index was calculated from the logarithmic transformation of TG/HDL‑C. Receiver operating characteristic curve was used to evaluate the diagnostic performance of log (TG/HDL‑C). Insulin and fasting glucose concentrations were used to determine homeostasis model assessment for insulin resistance (HOMA‑IR). Results: Compared with the patients with HbA1c <8%, log (TG/HDL‑C) was significantly higher in the patients with HbA1c ≥8% (p = 0.025). The atherogenic index was a biomarker for the prediction of T2D patients with HbA1c ≥8% versus patients with HbA1c <8%, as shown in the area under the curve (AUC = 0.61, P = 0.013). The best cut‑off point of log (TG/ HDL‑C) for the discrimination between patients with HbA1c ≥8% versus patients with HbA1c <8% determined to be 0.44. Atherogenic index was significantly and positively correlated with HOMA‑IR in female patients (r = 0.313, P = 0.003) and in patients with an age ≥5o (r = 0.253, P = 0.021). Conclusion: The log (TG/HDL‑C) in addition to its known association with enhanced CVD risk could be considered as a biomarker to predict T2D patients with poor glycemic control. Therefore, the increased ratio may provide a simple and useful way of identifying poor glycemic T2D patients who are possibly to be at elevated risk of CVD.


Biomarker; cardiovascular disease; HbA1c; Log (TG/HDL‑C); type 2 diabetes

Full Text:



Jones PH. Expert perspective: Reducing cardiovascular risk

in metabolic syndrome and type 2 diabetes mellitus beyond

low‑density lipoprotein cholesterol lowering. Am J Cardiol


Shokri F, Ghaedi H, Fard SG, Movafagh A, Abediankenari S,

Mahrooz A, et al. Impact of ATM and SLC22A1 polymorphisms

on therapeutic response to metformin in Iranian diabetic patients.

Int J Mol Cell Med 2016;5:1‑7.

Zargari M, Sharafeddin F, Mahrooz A, Alizadeh A, Masoumi P.

The common variant Q192R at the paraoxonase 1 (PON1)

gene and its activity are responsible for a portion of the

altered antioxidant status in type 2 diabetes. Exp Biol Med


Fruchart J‑C, Sacks F, Hermans MP, Assmann G, Brown WV,

Ceska R, et al. The residual risk reduction initiative: A call

to action to reduce residual vascular risk in patients with

dyslipidemia. Am J Cardiol 2008;102:1K‑34K.

Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK.

Cardiovascular risk factors in confirmed prediabetic individuals:

does the clock for coronary heart disease start ticking before the

onset of clinical diabetes? JAMA 1990;263:2893‑8.

Vega GL, Barlow CE, Grundy SM, Leonard D, DeFina LF.

Triglyceride–to–high‑density‑lipoprotein‑cholesterol ratio is

an index of heart disease mortality and of incidence of type 2

diabetes mellitus in men. J Invest Med 2014;62:345‑9.

Pishva H, Mehdipour P, Eshraghian MR, Mahboob SA.

Effects of eicosapentaenoic acid supplementation on lipid and

lipoprotein profile in hypertriglyceridemic subjects with different

proliferator‑activated receptor alpha genotypes. Int J Prevent

Med. 2014;5:333‑40.

Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M.

Relationship between serum lipoprotein ratios and insulin

resistance in obesity. Clin Chem 2004;50:2316‑22.

Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES,

et al. The legacy effect in type 2 diabetes: impact of early

glycemic control on future complications (the Diabetes & Aging

Study). Diabetes Care 2019;42:416‑26.

Association AD. 6. Glycemic Targets: Standards of Medical Care

in Diabetes—2020. Diabetes Care 2020;43(Suppl 1):S66‑S76.

Cortez‑Espinosa N, García‑Hernández MH, Reynaga‑Hernández

E, Cortés‑García JD, Corral‑Fernández NE, Rodríguez‑Rivera JG,

et al. Abnormal expression and function of Dectin‑1 receptor

in type 2 diabetes mellitus patients with poor glycemic

control (HbA1c >8%). Metabolism 2012;61:1538‑46.

Mahrooz A, Hashemi‑Soteh MB, Heydari M, Boorank R,

Ramazani F, Mahmoudi A, et al. Paraoxonase 1 (PON1)‑L55M

among common variants in the coding region of the paraoxonase

gene family may contribute to the glycemic control in type 2

diabetes. Clin Chim Acta 2018;484:40‑6.

Hosseinzadeh P, Javanbakht MH, Mostafavi S‑A, Djalali M,

Derakhshanian H, Hajianfar H, et al. Brewer’s yeast improves

glycemic indices in type 2 diabetes mellitus. Int J Prev Med


Budoff M. Triglycerides and triglyceride‑rich lipoproteins in

the causal pathway of cardiovascular disease. Am J Cardiol


American Diabetes Association. Standards of Medical Care

in Diabetes‑2017 Abridged for Primary Care Providers. Clin

Diabetes 2017;35:5‑26.

Variji A, Shokri Y, Fallahpour S, Zargari M, Bagheri B,

Abediankenari S, et al. The combined utility of

myeloperoxidase (MPO) and paraoxonase 1 (PON1) as

two important HDL‑associated enzymes in coronary artery

disease: Which has a stronger predictive role? Atherosclerosis


McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M,

Waters D, et al. Is there a simple way to identify insulin‑resistant

individuals at increased risk of cardiovascular disease? Am J

Cardiol 2005;96:399‑404.

Zhou M, Li Z, Min R, Dong Y, Sun Q, Li Y. Log (TG)/

HDL‑C ratio as a predictor of decreased islet beta cell

function in patients with type 2 diabetes: 6‑year cohort

study. J Diabetes 2015;7:689‑98.

Lim T‑K, Lee HS, Lee Y‑J. Triglyceride to HDL‑cholesterol

ratio and the incidence risk of type 2 diabetes in community

dwelling adults: A longitudinal 12‑year analysis of the Korean

Genome and Epidemiology Study. Diabetes Res Clin Pract


Viktorinova A, Svitekova K, Stecova A, Krizko M. Relationship

between selected oxidative stress markers and lipid risk factors

for cardiovascular disease in middle‑aged adults and its possible

clinical relevance. Clin Biochem 2016;49:868‑72.

Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M,

et al. The triglyceride‑to‑HDL cholesterol ratio: Association

with insulin resistance in obese youths of different ethnic

backgrounds. Diabetes Care 2011;34:1869‑74.

Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic

index of plasma in patients with type 2 diabetes. Clin Chem